Should I buy Jazz Pharmaceuticals (JAZZ) stock or is it too late?

Jazz Pharmaceuticals · Health Care · price $210

See the full Jazz Pharmaceuticals (JAZZ) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Deutsche Bank — 68% of its targets hit on this sector (80 calls tested). It aims for $300 (+43 %), call made on August 27, 2026, maturing on August 27, 2027 (48 d ago).

The 10 reliable analysts $298+42 %

The 7 other firms $307+46 %

How to read it: the 10 reliable firms are not filtered by optimism — 10 aim above the price, 0 below, hence their $298 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Jazz Pharmaceuticals

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Morgan Stanley	83 %	+88.8 %	6	$322 +53%
B of A Securities	60 %	+58.3 %	5	$307 +46%
Citigroup	83 %	+53.5 %	6	$325 +54%
Piper Sandler	69 %	+37.2 %	13	$310 +47%
UBS	60 %	+31.4 %	10	$337 +60%
Needham	66 %	+25.6 %	29	$310 +47%
Cantor Fitzgerald	70 %	+24.6 %	10	$140 -33%
JP Morgan	100 %	+22.3 %	6	$276 +31%

In short — Should you invest in Jazz Pharmaceuticals? Is it too late, still worth it? Analysts are overwhelmingly positive (94% buy, median target $300, i.e. +43%), and the most reliable on JAZZ targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

94% of analysts rate it a buy (Buy consensus, 17 ratings) — a sign of market conviction.
Median price target $300, i.e. +43% from the current price ($210).
The most reliable firm on JAZZ, Truist Securities (100% hit rate, 4 scored calls), targets $286 (call made on October 7, 2026, maturing on October 7, 2027) (+36%) in its most recent call, and $230 (call made on January 12, 2026, maturing on January 12, 2027) (+9%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 17 ratings, 1 is neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on JAZZ

Median target $300 (+43%) · 17 ratings · Buy consensus

Strong Buy00%

Buy1694%

Hold16%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Jazz Pharmaceuticals now?

We won't decide for you. The facts: 94% of analysts rate it a buy, median target $300 (+43%), and Truist Securities (most reliable on JAZZ, 100%) targets $286. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Jazz Pharmaceuticals?

Not according to analysts: the median target ($300) is still +43% above the current price ($210) (most reliable on JAZZ: Truist Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Jazz Pharmaceuticals still worth investing in?

It depends on the gap between the price ($210) and its estimated value: analysts target $300 on median (+43%), with 94% buys (most reliable on JAZZ: Truist Securities, 100%). Cross-check with their real reliability on JAZZ and the cautions above. Information, not advice.

What's the main risk in buying JAZZ?

The consensus is not unanimous: of 17 ratings, 1 is neutral.

→ Go deeper: the full Jazz Pharmaceuticals profile (consensus, analyst reliability, price target, performance).